Pazopanib Tablet, Film Coated
Product Images NDC 13668-735

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Pazopanib (NDC 13668-735). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

400 mg (Bottle of 30 Tablets)

400 mg (Bottle of 30 Tablets)
Pazopanib Tablets 400 mg film-coated oral tablets label from Torrent Pharmaceuticals Limited. The carton contains 30 tablets. The label includes storage instructions (20°C to 25°C), a warning about the safety seal, and directs to accompanying prescribing information. The label also features the NDC number 13668-735-30 and the Torrent Pharma logo.*
FDA Label Image

Chemical Structure (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 01)

Chemical Structure (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 01)
Chemical structure diagram of pazopanib hydrochloride, showing the molecular arrangement and bonds of its chemical formula as related to the active ingredient pazopanib.*
FDA Label Image

Figure-1 (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 02)

Figure-1 (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 02)
A Kaplan-Meier survival curve comparing proportion progression-free over time in months between pazopanib tablets and placebo groups. The graph includes median progression-free survival times with statistical data: 9.2 months for pazopanib (N=290) and 4.2 months for placebo (N=145), along with hazard ratio and confidence interval details.*
FDA Label Image

Figure-2 (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 03)

Figure-2 (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 03)
This Kaplan-Meier plot compares the proportion of patients progression-free over time (in months) between pazopanib tablets (N=246) and placebo (N=123). Pazopanib shows a median progression-free duration of 4.6 months versus 1.6 months for placebo, with associated hazard ratio and confidence interval data indicated.*
FDA Label Image

Torrent Logo (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 04)

FDA Label Image

Image (C72f5cb9 C582 4434 9979 Dee44c4a9ee3 167 2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.